Drug maker Cadila Healthcare Ltd, also known as Zydus Cadila, has acquired two abbreviated new drug applications (ANDA) from Teva Pharmaceutical Industries Ltd that are being divested by Israel-based company as a pre-condition to its acquisition of Allergan Plc.’s generic business.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
